Evidence map›Paper›PMID 29498218›Full record

ReviewClinical and translational science2018

Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation.

Susan M Keating, D Lansing Taylor, Anne L Plant, E David Litwack, Peter Kuhn, Emily J Greenspan, Christopher M Hartshorn, Caroline C Sigman, Gary J Kelloff, David D Chang and 3 more

Abstract readReview
In one paragraph

Review in Clinical and translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. A Flow Cytometric Method for Isolating Cystic Fibrosis Airway Macrophages from Expectorated Sputum.American journal of respiratory cell and molecular biology · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Susan M KeatingCCS Associates, San Jose, California, USA.
D Lansing TaylorUniversity of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Anne L PlantBiosystems and Biomaterials Division Materials Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland, USA.
E David LitwackOffice of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland, USA.
Peter KuhnUniversity of Southern California, Los Angeles, California, USA.
Emily J GreenspanCenter for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland, USA.
Christopher M HartshornNational Cancer Institute, Bethesda, Maryland, USA.
Caroline C SigmanCCS Associates, San Jose, California, USA.
Gary J KelloffNational Cancer Institute, Bethesda, Maryland, USA.
David D ChangKite Pharma, Inc., Santa Monica, California, USA.
Gregory FribergAmgen, Thousand Oaks, California, USA.
Jerry S H LeeCenter for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland, USA.
Keisuke KuidaDeciphera Pharmaceuticals, LLC, Waltham, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high-content interrogation of single cells with platforms optimized for the multiparameter characterization of cells in liquid and solid biopsy samples can enable characterization of heterogeneous populations of cells ex vivo. Doing so will advance the diagnosis, prognosis, and treatment of cancer and other diseases. However, it is important to understand the unique issues in resolving heterogeneity and variability at the single cell level before navigating the validation and regulatory requirements in order for these technologies to impact patient care. Since 2013, leading experts representing industry, academia, and government have been brought together as part of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to foster the potential of high-content data integration for clinical translation.

Indexed as

BiopsyHealth Plan ImplementationHumansNational Institutes of Health (U.S.)NeoplasmsPrognosisSingle-Cell AnalysisTranslational Research, BiomedicalUnited StatesValidation Studies as Topic

Identifiers

PMID29498218
PMCPMC5944591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.